| Value | ₹423.6 Cr |
|---|
BSE filing, NSE: PASUPTAC. Summary written from the filing by ALFA Finder's alert engine.
Pasupati Acrylon Ltd: key numbers
- Share price
- ₹70.65
- Market cap
- ₹629.7 Cr
- Revenue (annual)
- ₹1,010 Cr
- Net profit (annual)
- ₹69.91 Cr
- P/E (TTM)
- 6.6×Sector 52.8×
- Promoter holding
- 65.87%+0.00% QoQ
- FII holding
- 0.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pasupati Acrylon Ltd
All →Pasupati Acrylon Board Meeting Date
Pasupati Acrylon will hold a board meeting on 2 November 2026 to consider unaudited standalone results for the quarter and half year ended September 2026. The trading window is closed from 1 October to 4 November 2026.
Pasupati Acrylon Other Announcement
Pasupati Acrylon Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Pasupati Acrylon Capacity Expansion
Pasupati Acrylon received approval from the Uttar Pradesh Excise Department to increase its ethanol plant capacity from 180 KL per day to 240 KL per day.
- ethanol plant capacity
- 240.0 KL per day
Pasupati Acrylon Annual General Meeting
Pasupati Acrylon held its 43rd AGM on 9 Sep 2026, adopting FY26 financials, re-appointing a director, and ratifying cost auditor fees. No dividend or capital event was declared.
Pasupati Acrylon Other Announcement
Pasupati Acrylon Limited provided shareholders with a web-link and QR code to access the 43rd Annual Report and AGM Notice. The meeting is scheduled for September 9, 2026.
Pasupati Acrylon Annual Report
Pasupati Acrylon Limited has filed its Annual Report for FY 2025-26. The company's 43rd Annual General Meeting is scheduled for September 9, 2026.
Other credit rating announcements
All →Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Lloyds Metals & Energy Credit Rating
Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.
Ram Ratna Wires Credit Rating
CARE Ratings assigned and reaffirmed Ram Ratna Wires' bank facility ratings at CARE A-; Positive / CARE A2+ and revised outlook from Stable to Positive. The long-term bank facilities total Rs.1,046.45 Crore, with several facilities enhanced.
Adani Ports & Special Economic Zone Credit Rating
Fitch Ratings affirmed Adani Ports' Long-Term Foreign-Currency IDR and unsecured notes at 'BBB-' with a Stable outlook. The affirmation keeps the existing rating unchanged.
Capri Global Capital Credit Rating
India Ratings affirmed CGCL's credit rating at IND AA- with Positive outlook. A new Rs. 500 Cr bank loan facility was also assigned the same rating.